Sirtex Medical US Holdings, Inc. (Sirtex), a leading manufacturer of targeted liver cancer therapies, announced that enrollment in the US RESiN Registry has reached a milestone of 1,650 patients and ...
Approval was based on results from the DOORwaY90 trial, which demonstrated a 98.5% overall response rate and 100% local tumor control in patients treated with the SIR-Spheres Y-90 resin microspheres ...
Moreover, those patients treated with SIR-Spheres Y-90 resin microspheres who reported treatment-related side effects experienced a median of only 5 such events over the course of the SARAH study, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results